THE ROLE OF GENETIC POLYMORPHISM OF FILAGRIN PROTEIN IN THE COMBINATION OF ATOPIC DERMATITIS AND BRONCHIAL ASTHMA IN CHILDREN
DOI:
https://doi.org/10.11603/24116-4944.2021.1.12350Keywords:
children, atopic dermatitis, bronchial asthma, filagrinAbstract
The aim of the study – to investigate the features of the combined course of atopic dermatitis and bronchial asthma of children under the conditions of genetic polymorphism of the protein filagrin.
Materials and Methods. The course of filagrin-associated AD and comorbid bronchial asthma of children 3–12 years (n=51) was studied, representative groups were formed: children with atopic dermatiti (n=31), and children with atopic dermatitis and comorbid bronchial asthma AD/BA n=20). Filagrin gene polymorphism was determined by examining the buccal epithelium by the Delaport method. Sensitization to allergens was adopted on the basis of the level of specific Ig E. The impact of the disease on the quality of life (QOL) of children was performed using the CDLQI questionnaire (index of quality of life of the child at dermatological diseases).
Results and Discussion. Examination of children who most often had combining AD and asthma (78.4±5.76) % showed there was a variant of polymorphism R501X, a variant with a deletion of 2282del4 was registered in (7.8±3.76) %, and compound heterozygosity – in (13.7±4.81) % of patients. The associative connection of filagrin polymorphism with severe AD of children was demonstrated in children (54.9±6.97) % (χ2 = 16.2, p <0.05). No significant difference in the molecular characteristics of the filagrin gene in the comparison groups was found. Early manifestation of atopic dermatitis was observed in both groups. It was found that in both groups polysensitization to epidermal, fungal allergens, and Dermatofagoideus prevailed; food sensitization in the AD group was more common, in contrast, in the AD/BA group was dominated by pollen sensitization. Assessing the medical and social characteristics of the disease, the average quality of life in the group of AD was (20.4±2.1), and in the group of AD/BA (25.6±1.9), which indicates a significant impact of comorbid pathology on the child᾽s self-perception.
Conclusions. Early manifestation of atopic march of children with polymorphism in the filagrin protein gene requires measures to restore the epidermal barrier of the skin, which will prevent transcutaneous penetration of allergens and early sensitization of the body.
References
Anto, J.M., Bousquet, J., Akdis, M., Auffray, C., Keil, T., Momas, I., …, & Xu, C.J. (2017). Mechanisms of the development of allergy (MeDALL): introducing novel concepts in allergy pheno types. J. Allergy Clin. Immunol., 139 (2), 388-399. DOI: 10.1016/j.jaci.2016.12.940
Kabesch, M., & Tost, J. (2020). Recent findings in the genetics and epigenetics of asthma and allergy. Semin. Immunopathol., 42 (1), 43-60. DOI: 10.1007/s00281- 019-00777-w.
Levin, J., Friedlander, S.F., & Del Rosso, J.Q. (2013). Atopic dermatitis and the stratum corneum. Part 2: Other structural and functional characteristics of the stratum corneum barrier in atopic skin. J. Clin. Aesthet. Dermatol., 6 (11), 49-54.
Ballardini, N., Kull, I., Söderhäll, C., Lilja, G., Wickman, M., & Wahlgren, C.F. (2013). Eczema severity in preadolescent children and its relation to sex, filaggrin mutations, asthma, rhinitis, aggravating factors and topical treatment: a report from the BAMSE birth cohort. Br. J. Dermatol., 168 (3), 588-594. DOI: 10.1111/bjd.12196.
Liang, Y., Chang, C., & Lu, Q. (2016). The genetics and epigenetics of atopic dermatitis–filaggrin and other polymorphisms. Clin. Rev. Allergy Immunol., 51 (3), 315-328. DOI: 10.1007/s12016-015-8508-5.
Portelli, M.A., Hodge, E., & Sayers, I. (2015). Genetic risk factors for the development of allergic disease identified by genome–wide association. Clin. Exp. Allergy, 45 (1), 21-31. DOI: 10.1111/cea.12327.
McAleer, M.A., & Irvine, A.D. (2013). The multifunctional role of filaggrin in allergic skin disease. J. Allergy Clin. Immunol., 131 (2), 280-291. DOI: 10.1016/j.jaci.2012.12.668.
Namazova-Baranova, L.S., Baranov, A.A., Kubanova, A.A., Ilina, N.I., Kurbacheva, O.M., Vishneva, E.A., ..., & Voznesenskaya, N.I. (2016). Atopic dermatitis in children: current clinical guidelines for diagnosis and therapy. Curr. Pediatrics, 15 (3), 279-294. DOI: https://doi.org/10.15690/vsp.v15i3.1566.
Volosovets, A.P., Krivopustov, S.P., & Pavlik, Ye.V. (2013). Rol fillagrina v allergologii detskogo vozrasta [The role of phillagrin in allergology of children]. Zdorovye rebenka – Child Health, 2, 12-15 [in Russian].
Lodén, M. (2016). Treatments improving skin barrier function. Curr. Probl. Dermatol., 49, 112-122. DOI: 10.1159/000441586.
Besh, L.V. (2013). Atopichni dermatyty u ditei: analiz diahnostychnykh i taktychnykh pomylok [Atopic dermatitis in children: analysis of diagnostic and tactical errors]. Zdorovia Ukrainy. Tematychnyi nomer, alerholohiia – Health of Ukraine. Thematic Issue, Allergology., 52-53 [in Ukrainian].
Balabolkin, I.I., Larkova, I.A., Bulgakova, V.A., Pinelis, V.G., Gusar, V.A., & Janin, I.S. (2016). Mutations in the gene filaggrin in patients with atopic dermatitis as a risk factor for the severity of the disease. Allergy, 71 (S102), 300-301. Retrieved from: https://onlinelibrary.wiley.com/doi/epdf/10.1111/all.12974.
Kalyuzhnaya, L.D. (2014). Raznoobraziye topicheskoy terapii atopicheskogo dermatita kak faktor preodoleniya kortikofobii [Variety of topical therapy for atopic dermatitis as a factor in overcoming corticophobia]. Klinichna imunologiya. Alergologiya. Infektologiya – Clinical Immunology. Allergology. Infectology, 8 (77), 19-23 [in Russian].
Lowe, K.E., Zein, J., Hatipoglu, U., & Attaway, A. (2020). Atopic eczema and fracture risk in adults: A population–based cohort study. J. Allergy Clin. Immunol., 145 (2), 563-571. DOI: 10.1016/j.jaci.2019.09.015.
Dennin, M., & Lio, P.A. (2017). Filaggrin and childhood eczema. Arch. Dis. Child., 102 (12), 1101-1102. DOI: 10.1136/archdischild–2017–313010.
Kim, K.H. (2013). Overview of atopic dermatitis. Asia Pac. Allergy, 3 (2), 79-87. DOI: https://doi.org/10.5415/apallergy.2013.3.2.79.
Kim, S.Y., Yang, S.W., Kim, H.L., Kim, S.H., Kim, S.J., Park, S.M., …, & Um, J.Y. (2013). Association between P478S polymorphism of the filaggrin gene & atopic dermatitis. Indian J. Med. Res., 138 (6), 922-927.
Zuyeva, M.I. (2011). Mutatsii R501X i 2282del4 gena FLG u bolnykh allergodermatozami [R501X and 2282del4 mutations of FLG gene in allergodermatoses patients]. Visnyk Kharkivskoho natsionalnoho universytetu imeni V. N. Karazina. Seriya: Biolohiya – Bulletin of V.N. Karazin Kharkiv National University. Series: Biology, 13 (947), 93-97. Retrieved from: http://nbuv.gov.ua/UJRN/VKhb_2011_947_13_16 [in Russian].
Dytiatkovskyi, V.O. (2017). Atopichnyi marsh u pediatrii: henotyp-asotsiiovani mekhanizmy. Chastyna 1. Henotyp-asotsiiovani mekhanizmy khvorob atopichnoho marshu v ditei [Atopic march in pediatrics: genotype-associated mechanisms. Part 1. Genotype-associated mechanisms of the atopic march in children]. Zdorovia dytyny – Child Health, 12 (4), 498-504. Retrieved from: http://nbuv.gov.ua/UJRN/Zd_2017_12_4_14. DOI: 10.22141/2224-0551.12.4.2017.107632 [in Ukrainian].
Volosovets, O.P., Dosenko, V.Ye., Kryvopustov, S.P., Pavlyk, O.V., Yemets, O.V., & Stroi, D.O. (2015). Funktsionalne znachennia odnonukleotydnoho polimorfizmu (rs11204981) v heni filahhrinu (FLG) dlia likuvannia bronkhialnoi astmy u ditei z atopichnym dermatytom [Functional significance of single-nucleotide polymorphism (rs11204981) in filaggrin (flg) gene for the treatment of bronchial asthma in children with atopic dermatitis]. Zdorovye rebenka – Child Health, 1 (60), 14-18 [in Ukrainian].
Smieszek, S.P., Welsh, S., Xiao, C., Wang, J., Polymeropoulos, C., Birznieks, G., & Polymeropoulos, M.H. (2020). Correlation of age-of-onset of atopic dermatitis with filaggrin loss-of-function variant status. Sci. Rep., 10 (1), 2721. DOI: 10.1038/s41598-020-59627-7.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Actual Problems of Pediatrics, Obstetrics and Gynecology
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish in this journal agree to the following terms:
1. The authors reserve the right to authorship of the work and pass the journal right of first publication of this work is licensed under a Creative Commons Attribution License, which allows others to freely distribute the work published with reference to the authors of the original work and the first publication of this magazine.
2. Authors are entitled to enter into a separate agreement on additional non-exclusive distribution of work in the form in which it was published in the magazine (eg work place in the electronic repository institution or publish monographs in part), provided that the reference to the first publication of this magazine.
3. Policy magazine allows and encourages authors placement on the Internet (eg, in storage facilities or on personal websites) manuscript of how to submit the manuscript to the editor and during his editorial processing, since it contributes to productive scientific discussion and positive impact on the efficiency and dynamics of citing published work (see. The Effect of Open Access).
